The influence of genetics on therapeutic developments in pulmonary alveolar proteinosis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: Pulmonary alveolar proteinosis (PAP) is characterized by the massive accumulation of lipoproteinaceous material within alveoli, which results in progressive respiratory failure. The abnormalities in surfactant clearance are caused by defective pulmonary macrophages, whose terminal differentiation is GM-CSF-dependent. In hereditary PAP, the rupture of GM-CSF signaling is because of mutations in the GM-CSF receptor genes. This review focus on the innovative technologies of gene-correction proposed for the development of new therapeutic strategies, for hereditary PAP patients. RECENT FINDINGS: Hematopoietic stem cell gene therapy has been successfully experimented in murine models to restore the expression of the GM-CSF receptor, however, a therapeutic approach based on bone marrow transplantation requires a preconditioning, which could be hazardous in PAP patients, who are highly susceptible to pulmonary infections. Gene-corrected pulmonary macrophages, administered directly to the lung, could represent an improved approach. Finally, patient-derived induced pluripotent stem cells seem to be promising to overcome the limited availability of primary patient cells and to generate gene-corrected macrophages, able to recover pulmonary surfactant clearance. SUMMARY: WLL is the gold standard therapy for PAP. However, its use in hereditary PAP is limited by the difficulty of performing this technique in paediatric patients and by its purely symptomatic efficacy. The recent advances in genome engineering could provide efficacious strategies for clinical application.

Original languageEnglish
Pages (from-to)294-299
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Volume25
Issue number3
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Pulmonary Alveolar Proteinosis
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Alveolar Macrophages
Granulocyte-Macrophage Colony-Stimulating Factor
Genes
Therapeutics
Pulmonary Surfactants
Induced Pluripotent Stem Cells
Lung
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Bone Marrow Transplantation
Surface-Active Agents
Respiratory Insufficiency
Genetic Therapy
Rupture
Macrophages
Genome
Pediatrics
Technology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The influence of genetics on therapeutic developments in pulmonary alveolar proteinosis. / Campo, Ilaria.

In: Current Opinion in Pulmonary Medicine, Vol. 25, No. 3, 01.05.2019, p. 294-299.

Research output: Contribution to journalArticle

@article{c22451e35ca648e09329fba3c3db1cb2,
title = "The influence of genetics on therapeutic developments in pulmonary alveolar proteinosis",
abstract = "PURPOSE OF REVIEW: Pulmonary alveolar proteinosis (PAP) is characterized by the massive accumulation of lipoproteinaceous material within alveoli, which results in progressive respiratory failure. The abnormalities in surfactant clearance are caused by defective pulmonary macrophages, whose terminal differentiation is GM-CSF-dependent. In hereditary PAP, the rupture of GM-CSF signaling is because of mutations in the GM-CSF receptor genes. This review focus on the innovative technologies of gene-correction proposed for the development of new therapeutic strategies, for hereditary PAP patients. RECENT FINDINGS: Hematopoietic stem cell gene therapy has been successfully experimented in murine models to restore the expression of the GM-CSF receptor, however, a therapeutic approach based on bone marrow transplantation requires a preconditioning, which could be hazardous in PAP patients, who are highly susceptible to pulmonary infections. Gene-corrected pulmonary macrophages, administered directly to the lung, could represent an improved approach. Finally, patient-derived induced pluripotent stem cells seem to be promising to overcome the limited availability of primary patient cells and to generate gene-corrected macrophages, able to recover pulmonary surfactant clearance. SUMMARY: WLL is the gold standard therapy for PAP. However, its use in hereditary PAP is limited by the difficulty of performing this technique in paediatric patients and by its purely symptomatic efficacy. The recent advances in genome engineering could provide efficacious strategies for clinical application.",
author = "Ilaria Campo",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MCP.0000000000000576",
language = "English",
volume = "25",
pages = "294--299",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The influence of genetics on therapeutic developments in pulmonary alveolar proteinosis

AU - Campo, Ilaria

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: Pulmonary alveolar proteinosis (PAP) is characterized by the massive accumulation of lipoproteinaceous material within alveoli, which results in progressive respiratory failure. The abnormalities in surfactant clearance are caused by defective pulmonary macrophages, whose terminal differentiation is GM-CSF-dependent. In hereditary PAP, the rupture of GM-CSF signaling is because of mutations in the GM-CSF receptor genes. This review focus on the innovative technologies of gene-correction proposed for the development of new therapeutic strategies, for hereditary PAP patients. RECENT FINDINGS: Hematopoietic stem cell gene therapy has been successfully experimented in murine models to restore the expression of the GM-CSF receptor, however, a therapeutic approach based on bone marrow transplantation requires a preconditioning, which could be hazardous in PAP patients, who are highly susceptible to pulmonary infections. Gene-corrected pulmonary macrophages, administered directly to the lung, could represent an improved approach. Finally, patient-derived induced pluripotent stem cells seem to be promising to overcome the limited availability of primary patient cells and to generate gene-corrected macrophages, able to recover pulmonary surfactant clearance. SUMMARY: WLL is the gold standard therapy for PAP. However, its use in hereditary PAP is limited by the difficulty of performing this technique in paediatric patients and by its purely symptomatic efficacy. The recent advances in genome engineering could provide efficacious strategies for clinical application.

AB - PURPOSE OF REVIEW: Pulmonary alveolar proteinosis (PAP) is characterized by the massive accumulation of lipoproteinaceous material within alveoli, which results in progressive respiratory failure. The abnormalities in surfactant clearance are caused by defective pulmonary macrophages, whose terminal differentiation is GM-CSF-dependent. In hereditary PAP, the rupture of GM-CSF signaling is because of mutations in the GM-CSF receptor genes. This review focus on the innovative technologies of gene-correction proposed for the development of new therapeutic strategies, for hereditary PAP patients. RECENT FINDINGS: Hematopoietic stem cell gene therapy has been successfully experimented in murine models to restore the expression of the GM-CSF receptor, however, a therapeutic approach based on bone marrow transplantation requires a preconditioning, which could be hazardous in PAP patients, who are highly susceptible to pulmonary infections. Gene-corrected pulmonary macrophages, administered directly to the lung, could represent an improved approach. Finally, patient-derived induced pluripotent stem cells seem to be promising to overcome the limited availability of primary patient cells and to generate gene-corrected macrophages, able to recover pulmonary surfactant clearance. SUMMARY: WLL is the gold standard therapy for PAP. However, its use in hereditary PAP is limited by the difficulty of performing this technique in paediatric patients and by its purely symptomatic efficacy. The recent advances in genome engineering could provide efficacious strategies for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85063930619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063930619&partnerID=8YFLogxK

U2 - 10.1097/MCP.0000000000000576

DO - 10.1097/MCP.0000000000000576

M3 - Article

C2 - 30865035

AN - SCOPUS:85063930619

VL - 25

SP - 294

EP - 299

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 3

ER -